Annual Report and Notice of AGM

4D pharma plc

(the "Company" or "4D")

Annual Report and Notice of AGM

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, announces that the Annual Report and Accounts for the year to 31 December 2018 and Notice of the Company's Annual General Meeting ("AGM") have been posted to shareholders.

An electronic copy of each of the Annual Report and Accounts and the Notice of AGM is available on the Company's website, www.4dpharmaplc.com.

The AGM will be held in the Chicago Room, Sofitel, Terminal 5, Wentworth Drive, London Heathrow Airport, Hounslow TW6 2GD, at 10 a.m. on Thursday 20 June 2019.

For further information please contact:

About 4D

Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria based on a deep understanding of function and mechanism. 4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has three clinical studies in progress, namely a Phase II clinical study of Blautix® in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours and a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. Other focus programmes include disease areas such as asthma and CNS disease.